Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Longeveron Inc
(NQ:
LGVN
)
2.570
-0.060 (-2.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Longeveron Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug
January 06, 2023
Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.
Via
Benzinga
Elon Musk Is a Genius Market Timer. That’s Bad News for Tesla (TSLA) Stock.
December 19, 2022
Elon Musk is great at timing the market. He's selling TSLA stock now, and savvy investors would be wise to follow suit.
Via
InvestorPlace
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket
December 13, 2022
Gainers Netcapital Inc. (NASDAQ: NCPL) shares rose 91.3% to $2.65 in pre-market trading following Q2 results. Netcapital posted Q2 earnings of $0.04 per share on sales of $1.78 million.
Via
Benzinga
Longeveron: Q2 Earnings Insights
August 12, 2022
Longeveron (NASDAQ:LGVN) reported its Q2 earnings results on Friday, August 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
How to Find Stocks That Rise 10x
October 10, 2022
Investors looking for 10X stocks should prioritize companies in high-growth areas that demonstrate high earnings quality.
Via
InvestorPlace
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
October 05, 2022
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
September 29, 2022
Gainers
Via
Benzinga
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
September 28, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 28, 2022
Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
September 28, 2022
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning.
Via
InvestorPlace
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
September 28, 2022
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.
Via
Benzinga
Longeveron's Return On Capital Employed Insights
September 09, 2022
Longeveron (NASDAQ:LGVN) brought in sales totaling $466 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 60.23%, resulting in a loss of $5.62 million.
Via
Benzinga
PFE, MRNA Stocks: What to Know as the FDA Approves New Booster Shots
August 31, 2022
Pfizer (PFE) and Moderna (MRNA) stocks are in the news Wednesday as the FDA approves new booster shots for the Covid-19 Omicron variant.
Via
InvestorPlace
Why Is Longeveron (LGVN) Stock on the Move Today?
August 31, 2022
Longeveron (LGVN) stock is on the move Wednesday after the FDA granted its fast-track designation for heart treatment Lomecel-B.
Via
InvestorPlace
Longeveron Shares Ascend As FDA Grants Fast Track Status To Congenital Heart Disease Candidate
August 31, 2022
Longeveron (NASDAQ: LGVN) received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS).
Via
Benzinga
EXCLUSIVE: Longeveron's Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants
August 31, 2022
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Longeveron Inc (NASDAQ: LGVN) Lomecel-B for the treatment of Hypoplastic Left Heart...
Via
Benzinga
European Patent Office Issues Intent To Grant Longeveron Patent Related To Methods To Monitor Efficacy Of Lomecel-B™ Cell Therapy
August 26, 2022
Longeveron Inc. (NASDAQ: LGVN) announced that the European Patent Office (EPO) had issued a notice of its intent to grant the Company a patent (EP Application No.
Via
Benzinga
EXCLUSIVE: Longeveron's Heart Disease Cell Therapy Poised To Secure European Patent
August 25, 2022
The European Patent Office has issued a notice of its intent to grant Longeveron Inc (NASDAQ: LGVN) a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 24, 2022
Via
Benzinga
Earnings Scheduled For August 12, 2022
August 12, 2022
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.
Via
Benzinga
Longeveron Earnings Preview
August 11, 2022
Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Friday, 2022-08-12. Here's what investors need to know before the announcement. Analysts estimate that Longeveron will...
Via
Benzinga
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
August 09, 2022
According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028.
Via
Benzinga
Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron
August 02, 2022
Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN)
Via
Benzinga
Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment
July 28, 2022
The U.S. Department of Veterans Affairs (VA) partnered with Longeveron Inc. (NASDAQ: LGVN) to explore the clinical-stage biotech’s novel cell therapies as a potential treatment for aging frailty.
Via
Benzinga
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.
Via
InvestorPlace
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
July 08, 2022
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market.
Via
Benzinga
Why U.S. Stocks Are Trading Higher After Rise In Jobless Claims
July 07, 2022
U.S. stocks traded higher this morning, following the release of data on initial jobless claims.
Via
Benzinga
This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session
July 07, 2022
Gainers United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp.
Via
Benzinga
7 Ways to Prepare for a Recession: An Investor’s Guide
June 24, 2022
There are plenty of ways to prepare for a recession. Here are seven ways you can make sure you're ready for whatever comes next.
Via
InvestorPlace
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
June 15, 2022
Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.